Nature Communications: Intranasal Macrocyclic Peptide Inhibitor Protects Against SARS-CoV-2 Omicron Variants
A Nature Communications paper introduced a broad-spectrum macrocyclic peptide inhibitor designed for intranasal administration that protects against multiple SARS-CoV-2 Omicron variants in preclinical models. The work expands the macrocyclic peptide modality beyond oncology into respiratory antivirals, where peptide stability and tissue penetration challenges have historically limited clinical translation. Published as Nature Communications article s41467-026-68462-9.